Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pausing GLP-1 drugs before colonoscopy: could a One-Week break improve bowel prep?

NCT ID NCT07736963

Knowledge-focused Sponsor: Fu Jen Catholic University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This trial tests whether stopping GLP-1 receptor agonists (medications like semaglutide and liraglutide) for one week before a colonoscopy leads to better bowel preparation and fewer repeat procedures. Researchers will compare bowel cleanliness and detection rates of polyps between people who pause the drug and those who continue it. The study includes adults aged 18 to 70 scheduled for a colonoscopy, aiming to establish clear discontinuation recommendations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonists (drugs like semaglutide and liraglutide)
What this could lead to
If it works, this could lead to clear guidelines on when to pause GLP-1 drugs before colonoscopy, improving procedure success and patient experience.
What could go wrong
This is a small, early-stage trial focused on a procedural question, not a new treatment. Results may not apply to all GLP-1 users or colonoscopy settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion Criteria for non GLP-1 user: * Individuals who are scheduled to undergo total colonoscopy for any reasons * Age between 18 to 70 years. * ECOG Performance status is 0 or 1. * Written consent to participate in the study has been obtained. * Outpatient department patient * Stop at least 3 days if current using medications that promote or inhibit gastrointestinal motility. Exclusion Criteria: * • Presence of severe comorbid conditions that preclude the safe performance of colonoscopy (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, chronic respiratory disease, or bleeding diathesis). * History of prior gastric, small bowel, or colorectal segmental resection (patients with isolated appendectomy are eligible). * Family history of hereditary colorectal cancer syndromes. * Current or prior diagnosis of inflammatory bowel disease. * Known colorectal polyposis syndromes. * Any other condition deemed inappropriate for study participation at the discretion of the treating physician. * Body mass index (BMI) \> 40 kg/m². * Diagnosis of liver cirrhosis. * Diagnosis of Parkinson's disease. * Diagnosis of dementia. * Use of tricyclic antidepressants or opioid medications for more than 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLP - 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLP - 1

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • FJUH

    RECRUITING

    New Taipei, Taiwan, 24352, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.